13 November 2015 - Baxalta Incorporated today announced that the European Commission has granted marketing authorisation for Obizur [Antihaemophilic Factor (Recombinant), Porcine Sequence].

For more details, go to: http://newsroom.baxalta.com/press-releases/press-release-details/2015/Baxalta-Gains-EU-Marketing-Authorization-to-Provide-OBIZUR-to-Adult-Patients-with-Acquired-Haemophilia-A/default.aspx